A Phase I/II, 2-Stage, Randomized, Double-Blind Trial of the Safety, Tolerability and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in Healthy Infants

Trial Profile

A Phase I/II, 2-Stage, Randomized, Double-Blind Trial of the Safety, Tolerability and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in Healthy Infants

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2012

At a glance

  • Drugs Aluminium phosphate; DTaP-hepatitis B-poliovirus vaccine; Hib vaccine conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Wyeth
  • Most Recent Events

    • 01 May 2010 Results reported in Pediatrics.
    • 04 Dec 2007 Status changed from no longer recruiting to completed, according to clinicaltrials.gov record
    • 11 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top